Commercial Model Innovation Key To Lowering China Compliance Risks
This article was originally published in PharmAsia News
Executive Summary
Balanced scorecards, big data, and platform strategies are among the new tools being employed by pharma companies ramping up compliance and lowering risks in China, where market access remains challenging and pricing pressures persistent. Such commercial model innovation should also improve physician interaction while providing new medical solutions, said executives at a recent RDPAC gathering in Beijing.
You may also be interested in...
2016 Review: Pricing, R&D Issues Dominate China Commercial Arena
2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.
Affordable PD-1 From China? CStone Going Global With EQRx Onboard
As the China immuno-oncology sector becomes increasingly crowded, CStone teams up with an innovative US business partner to go global.
Coronavirus Vaccines As A Public Good: How Reasonable Is Reasonable?
During a recent press briefing, health officials in China disclosed the country is poised to reach an annual production capacity of 610 million doses for coronavirus vaccines. But they said prices must be based on manufacturing costs and not driven by supply and demand.
Need a specific report? 1000+ reports available
Buy Reports